Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/04/2005WO2005026167A8 Process for preparing famciclovir
08/04/2005WO2005023175A3 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
08/04/2005WO2005020885A3 Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
08/04/2005WO2005018557A3 Substituted pyridinones
08/04/2005WO2005011648A3 Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems
08/04/2005WO2005010481A3 Preparation and use of gold glyconanoparticles
08/04/2005WO2005009322A3 Delivery system for topical medications
08/04/2005WO2005007150A3 Method for inhibiting protein synthesis in sperm
08/04/2005WO2005007129A3 Topical formulations with bioactive components
08/04/2005WO2005004919A8 Extended release systems for macrolide antibiotics
08/04/2005WO2005000236A3 Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
08/04/2005WO2004108093A3 Antiseptic compositions, methods and systems
08/04/2005WO2004091485A3 Aminoquinoline compounds
08/04/2005WO2004076417A9 Novel crystalline forms of trandolapril
08/04/2005WO2004075840A9 Selective non-steroidal glucocorticoid receptor modulators
08/04/2005WO2004064782A3 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005WO2004004658A3 Methods and compositions relating to isoleucine boroproline compounds
08/04/2005WO2003000009A3 Stimulation of vascularization with vegf-b
08/04/2005US20050172352 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/04/2005US20050171464 Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
08/04/2005US20050171366 Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde; efficient synthesis of intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors
08/04/2005US20050171361 Production of delta 9 tetrahydrocannabinol
08/04/2005US20050171354 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for prophylaxis of cardiovascular disorders
08/04/2005US20050171353 Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
08/04/2005US20050171352 Process for the preparation of 4-(8-chloro-5 6-dihydro-11h-benzo-(5 6)-cyclohepta-(1 2b)-pyridin-11-ylidene-1-piperidiniecarboxylic acid ethyl ester (loratadine)
08/04/2005US20050171350 Benzhydryl derivatives
08/04/2005US20050171347 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/04/2005US20050171346 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections
08/04/2005US20050171345 Pteridine compounds for the treatment of psoriasis
08/04/2005US20050171338 Mammalian tribbles signaling pathways and methods and reagents related thereto
08/04/2005US20050171335 Novel antimicrobial peptide and use thereof
08/04/2005US20050171286 Copolymer-1 improvements in compositions of copolymers
08/04/2005US20050171214 Utilizing astaxanthin and/or ester as food and/or drink nutritional supplement; supporting and restoring human eyes automatic focusing ability
08/04/2005US20050171212 Potentiation with zeaxanthin; imparting yellowish color prior to administering light activated drugs; wet (exudative) macular degeneration
08/04/2005US20050171210 Compositions and methods for treatment of cardiovascular disorders and diseases
08/04/2005US20050171208 Histone deacetylase inhibitors
08/04/2005US20050171207 one or more HMG-CoA-reductase inhibitors and one or more R NSAIDs comprising R-flurbiprofen or a pharmaceutically acceptable salt or ester thereof; Alzheimer's disease, dementia, mild cognitive impairment
08/04/2005US20050171206 sodium, potassium, magnesium, calcium and arginine salts of phenylbutyrate; treatment of spinal muscular atrophy; an autosomal recessive condition
08/04/2005US20050171204 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance
08/04/2005US20050171203 includes water, at least one preservative, at least one taste-masking agent, and an optional viscosity control agent; suitable for oral administration
08/04/2005US20050171202 Modulation of signal transduction
08/04/2005US20050171200 Use of EPA and DHA in secondary prevention
08/04/2005US20050171199 Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
08/04/2005US20050171198 SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
08/04/2005US20050171197 (a) asymmetrically reducing bromoacetophenone compound to a chiral phenyl-bromoethanol; (b) displacing the bromo group by primary amine to produce protected chiral phenylethanolamine, and (c) removing protecting groups to convert it to chiral phenylethanolamine; beta -adrenergic receptor agonist; asthma
08/04/2005US20050171196 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
08/04/2005US20050171195 presynaptic terminals in central and peripheral nervous systems; release of neurotransmitter glutamate; excitotoxicity and responses to injury; N-[2,2-dichloro-1-({(cyanoimino)[(2-methoxy-3-pyridinyl)amino]methyl}amino)propyl]-2-(3,4-dimethoxyphenyl)acetamide
08/04/2005US20050171194 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions
08/04/2005US20050171193 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
08/04/2005US20050171192 treating or preventing reactive oxygen species (ROS)-mediated oxidative damage to bone cells and tissues; histamine receptor agonists, histamine salts, histamine prodrugs, NADPH-oxidase inhibitors, serotonin, serotonin (5HT) receptor agonists
08/04/2005US20050171191 citrus-based furocoumarins; for dietary supplements or medicinal foods; bioavailability
08/04/2005US20050171190 Substituted 5-chroman-5-YL-ethylamine compounds and their use for the treatment of glaucoma
08/04/2005US20050171189 Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a mehtod for effective purification of racemic lasofoxifene
08/04/2005US20050171188 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
08/04/2005US20050171187 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate
08/04/2005US20050171186 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171182 inhibitor of the mutant receptor tyrosine kinase and an MEK inhibitor; kits
08/04/2005US20050171180 by targeting beta and gamma secretase enzyme decreases production of amyloid precursor protein; 5-Chloro-N-{2-ethyl-1-[1-(4-methoxybenzyl)-1H-pyrazol-5-yl]butyl}thiophene-2-sulfonamide; Alzheimer's Disease, Down's Syndrome, cognitive decline
08/04/2005US20050171178 Exo-1-methyl-1H-imidazole-4-sulfonic acid {3-[6-ethyl-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-amide; opioid receptors (mu, kappa and delta) antagonists; not substrate of the variable enzyme CYP2D6; addiction to an opiates, alcohol; obesity
08/04/2005US20050171177 Method of treatment of Candida isolates
08/04/2005US20050171176 Pharmaceutically active aromatic guanylhydrazones
08/04/2005US20050171175 Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171173 Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
08/04/2005US20050171172 platelet derived growth factor receptor; anticarcinogenic; leukemia; specific kinase inhibitors; accurate targeting with limited inhibition of other pathways; reduced toxicity
08/04/2005US20050171171 colony-stimulating factor receptor (c- FMS)-like tyrosine kinase 3; anticarcinogenic; leukemia;specific kinase inhibitors; accurate targeting with limited inhibition of other pathways; reduced toxicity
08/04/2005US20050171169 Combination chemotherapy for helminth infections
08/04/2005US20050171168 Use of riluzole for the treatment of multiple sclerosis
08/04/2005US20050171167 Infusion fluid with a buffer and a pH-adjusting base; low pH differential reduces acid-catalyzed hydrolysis for enhanced stability; anticancer; antihyperproliferative; kit
08/04/2005US20050171166 Use as inhibitors of FK560 binding proteins (FKBPs) enzyme activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injury or other related diseases
08/04/2005US20050171163 MCP-1 receptor antagonists and methods of use thereof
08/04/2005US20050171162 Crystals of benzimidazole compounds
08/04/2005US20050171161 antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion
08/04/2005US20050171160 Doxepin analogs and methods of use thereof
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171155 Method to separate stereoisomers
08/04/2005US20050171154 Carboxylic acid amides
08/04/2005US20050171153 Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
08/04/2005US20050171152 N-( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; neurokinin NK-3 receptor antagonists; chemical intermediates; efficient process with increased yields; coupling an ortho-hydroxy acid with an amine; easy conversion side-product to desired; CNC disorders; anxiolitic and antidepressant
08/04/2005US20050171151 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
08/04/2005US20050171150 Selected from: LR-9 [4-(2-napthylcarboxamido) phenoxyisobutyric acid]; LR-74 [2-(8-quinolinoxy)propionic acid]; and LR-90 [methylene bis(4,4'-(2-chlorophenylureidophenoxyisobutyric acid)]; Menkes Disease, Wilson's Disease, or X-linked Cutis Laxa
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171144 Imidazo[1,2-a] pyridine anxiolytics
08/04/2005US20050171143 selective Chemoattractant receptor-homologous molecule expressed on Th2 cells ( CRTH2 receptor) antagonist; activities for eosinphil and basophil infiltration; indol/carbazol-sulfonamide derivatives; antiallergenic agent; asthma, allergic rhinitis and dermatitis, polyarteritis, autoimmune disease
08/04/2005US20050171142 New crystalline monohydrates and crystalline anhydrates of gaboxadol; suitable for oral dosage administration
08/04/2005US20050171141 Modulators of muscarinic receptors
08/04/2005US20050171140 Prevent cholesterol biosynthesis; moderating blood serum lipid ; antidiabetic agents; obesity; hypotensive agents; osteoporosis; Alzheimer's disease; cardiovascular disorders; hormone replacement therapy
08/04/2005US20050171139 With a full agonist of a dopamine D2-like receptor such as ropinirole, quinpirole, pramipexole, or apomorphine, alone or in combination with an atypical antipsychotic such as aripiprazole, risperidone, clozapine, olanzapine, quetiapine, or ziprasidone; schizophrenia, OCD, Tourette's Syndrome, dilusions
08/04/2005US20050171136 Modulators of the glucocorticoid receptor and method
08/04/2005US20050171135 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-Y1]-spiro[isobenzofuran-1(3H), 4'-piperidine]hydrohalogenides
08/04/2005US20050171134 such as 4-[4-(1-Amino-1-methylethyl)phenyl]-5-chloro-N-[4-(2-hydroxyethyl)phenyl]pyrimidine-2-amine used as tyrosine kinase inhibitors, for prophylaxis disease states associated with angiogenesis
08/04/2005US20050171133 Therapeutic compounds
08/04/2005US20050171132 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
08/04/2005US20050171131 Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171128 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2005US20050171127 Epzicom; coated tablet formulated with Ceolus" microcrystalline cellulose for once daily administration; synergistic HIV treatment
08/04/2005US20050171125 Novel alkoxypyridine-derivatives
1 ... 4590 4591 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 ... 7860